【DaYan BioMedical*】The Company's Board of Directors Approved the Consolidated Financial Statements for Q1 2026
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
DaYan BioMedical's Board of Directors has approved the consolidated financial statements for the first quarter of 2026 (115 ROC calendar). Key financial indicators show robust performance, including operating revenue of NT$463.842 million, pre-tax net profit of NT$140.409 million, and basic EPS of NT$0.13.